EUVIMEDEUVIMED entdecken
Vergleichsstudie

Staging of prostate cancer

D G Bostwick, R P Myers, J E Oesterling

Seminars in Surgical Oncology · 1994-01 · 10 (1) · 60-72

DOI: 10.1002/ssu.2980100110 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Seminars in Surgical Oncology, online erschienen am 22.08.2006. Verfasst von D G Bostwick und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Mayo Clinic, Rochester, MN 55905. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical and pathologic staging of prostate cancer involves determination of the anatomic extent and burden of tumor based on the best available data. Two major classification schemes are currently used: the modified American system and the TNM system [primary tumor (T), regional lymph node (N), and metastases (M)]. Both systems stratify patients according to the method of tumor detection, separating nonpalpable “incidental” prostate cancers detected during transurethral resection for clinically benign prostatic hyperplasia (BPH) and palpable cancers detected by digital rectal examination. These staging systems also recognize nonpalpable tumors detected by an elevated serum prostate‐specific antigen (PSA) level or an abnormal transrectal ultrasound image. Current staging is limited by a significant level of clinical understaging (up to 59%, in our experience) and over‐staging (up to 5%) according to comparison with pathologic examination of resected specimens. Proposed improvements in staging include preoperative systematic sextant biopsies to assess tumor volume, volume‐based prognostic index, and a multiple prognostic index. In this report, we evaluate the current aspects of clinical and pathologic staging of prostate cancer with emphasis on the early stages in which there is the greatest chance of cure. © 1994 Wiley‐Liss, Inc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Evaluation Studies as TopicHumansMaleNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingOutcome and Process Assessment, Health CarePrognosisProstate-Specific AntigenProstatic Neoplasms

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Pathology, Mayo Clinic, Rochester, MN 55905.

Zitieren

APA

Bostwick, D. G., Myers, R. P., & Oesterling, J. E. (1994). Staging of prostate cancer. Seminars in Surgical Oncology, 10(1), 60-72. https://doi.org/10.1002/ssu.2980100110

Vancouver

Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Seminars in Surgical Oncology. 1994;10(1):60-72. doi:10.1002/ssu.2980100110

BibTeX
@article{Bostwick1994,
  author = {Bostwick, D G and Myers, R P and Oesterling, J E},
  title = {Staging of prostate cancer},
  journal = {Seminars in Surgical Oncology},
  year = {1994},
  volume = {10},
  number = {1},
  pages = {60--72},
  doi = {10.1002/ssu.2980100110}
}
Kostenlos starten →